ABELARDO MARES: Open Payments
NPI 1780821868 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$813 in 20 payments from 8 companies in 2025. Trend: 2023 $371 · 2024 $56 · 2025 $813
Food & beverage: $813
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $265 |
| Neurocrine BioSciences, Inc. | 5 | $216 |
| Janssen Pharmaceuticals, Inc | 2 | $153 |
| ABBVIE INC. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: CAPLYTA, INGREZZA, INVEGA SUSTENNA, VRAYLAR, REXULTI, COBENFY, SPRAVATO, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
